{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T06:50:25Z","timestamp":1762498225031,"version":"build-2065373602"},"reference-count":10,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2017,12,1]],"date-time":"2017-12-01T00:00:00Z","timestamp":1512086400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,12,1]],"date-time":"2017-12-01T00:00:00Z","timestamp":1512086400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","eu-focus.europeanurology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology Focus"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1016\/j.euf.2018.03.005","type":"journal-article","created":{"date-parts":[[2018,3,15]],"date-time":"2018-03-15T18:42:35Z","timestamp":1521139355000},"page":"532-534","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["What is the Best Treatment Option for Coexisting Pelvic Floor Dysfunctions?"],"prefix":"10.1016","volume":"3","author":[{"given":"Manuela","family":"Tutolo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Enrico","family":"Ammirati","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Frank","family":"Van der Aa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.euf.2018.03.005_bib0005","doi-asserted-by":"crossref","first-page":"353","DOI":"10.4111\/icu.2017.58.5.353","article-title":"Evaluation of the incidence and risk factors associated with persistent frequency in interstitial cystitis\/bladder pain syndrome and the efficacy of antimuscarinic treatment","volume":"58","author":"Kim","year":"2017","journal-title":"Investig Clin Urol"},{"key":"10.1016\/j.euf.2018.03.005_bib0010","unstructured":"Burkhard FC, Bosch JLHR, Cruz GEL F, Nambiar AK, Thiruchelvam AT, Guidelines Associates: Amb\u00fchl D, Bedretdinova FF, Rozenberg BB. EAU Guidelines on urinary incontinence in adults n.d. http:\/\/uroweb.org\/guideline\/urinary-incontinence\/."},{"key":"10.1016\/j.euf.2018.03.005_bib0015","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1111\/j.1464-410X.2010.09697.x","article-title":"The long-term efficacy of sacral neuromodulation in the management of intractable cases of bladder pain syndrome: 14 years of experience in one centre","volume":"107","author":"Gajewski","year":"2011","journal-title":"BJU Int"},{"key":"10.1016\/j.euf.2018.03.005_bib0020","doi-asserted-by":"crossref","first-page":"75","DOI":"10.3390\/toxins8030075","article-title":"Adverse events of intravesical onabotulinumtoxina injection between patients with overactive bladder and interstitial cystitis\u2014different mechanisms of action of botox on bladder dysfunction?","volume":"8","author":"Kuo","year":"2016","journal-title":"Toxins (Basel)"},{"key":"10.1016\/j.euf.2018.03.005_bib0025","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1016\/j.juro.2007.10.032","article-title":"Botulinum A toxin intravesical injection in patients with painful bladder syndrome: 1-year followup","volume":"179","author":"Giannantoni","year":"2008","journal-title":"J Urol"},{"key":"10.1016\/j.euf.2018.03.005_bib0030","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1016\/j.juro.2015.01.086","article-title":"Diagnosis and treatment of interstitial cystitis\/bladder pain syndrome: AUA guideline amendment","volume":"193","author":"Hanno","year":"2015","journal-title":"J Urol"},{"key":"10.1016\/j.euf.2018.03.005_bib0035","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1001\/jama.2016.14617","article-title":"OnabotulinumtoxinA vs sacral neuromodulation on refractory urgency urinary incontinence in women","volume":"316","author":"Amundsen","year":"2016","journal-title":"JAMA"},{"key":"10.1016\/j.euf.2018.03.005_bib0040","doi-asserted-by":"crossref","first-page":"4283","DOI":"10.3390\/toxins7104283","article-title":"Long-term efficacy and safety of repeated intravescial onabotulinumtoxinA injections plus hydrodistention in the treatment of interstitial cystitis\/bladder pain syndrome","volume":"7","author":"Lee","year":"2015","journal-title":"Toxins (Basel)"},{"key":"10.1016\/j.euf.2018.03.005_bib0045","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1111\/bju.12571","article-title":"Long-term follow-up of sacral neuromodulation for lower urinary tract dysfunction","volume":"113","author":"Peeters","year":"2014","journal-title":"BJU Int"},{"key":"10.1016\/j.euf.2018.03.005_bib0050","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1111\/codi.12181","article-title":"Does sacral nerve stimulation improve global pelvic function in women?","volume":"15","author":"Jadav","year":"2013","journal-title":"Colorectal Dis"}],"container-title":["European Urology Focus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S240545691830083X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S240545691830083X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T06:46:07Z","timestamp":1762497967000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S240545691830083X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,12]]},"references-count":10,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["S240545691830083X"],"URL":"https:\/\/doi.org\/10.1016\/j.euf.2018.03.005","relation":{},"ISSN":["2405-4569"],"issn-type":[{"type":"print","value":"2405-4569"}],"subject":[],"published":{"date-parts":[[2017,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"What is the Best Treatment Option for Coexisting Pelvic Floor Dysfunctions?","name":"articletitle","label":"Article Title"},{"value":"European Urology Focus","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.euf.2018.03.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 European Association of Urology. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}